Australia’s Acrux Gets Favorable Results From Spray-On Contraceptive
This article was originally published in PharmAsia News
Executive Summary
Australian drug maker Acrux has Nestorone (progestin) in trial that could be the first spray-on contraceptive drug. Acrux is seeking commercial partners for the drug after it showed favorable results in trials. The drug, a fourth-generation progestin, is sprayed onto the skin with a small, hand-held device that allows delivery in smaller doses than usual to reduce side-effects. Nestorone is applied daily to the forearm where it passes through the skin into the bloodstream, reducing the amount of progestin needed in oral doses. (Click here for more
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.